Health & bio
Arvinas Veppanu Becomes First PROTAC FDA Approval for ESR1-Mutant Breast Cancer
May 1 FDA approval of Arvinas' vepdegestrant (Veppanu) for ER+/HER2–/ESR1-mutant advanced/metastatic breast cancer marks first commercial PROTAC (heterobifunctional protein degrader) success.
Primary sources · 2